SCHEMBL19220799

SCHEMBL19220799

COc1cc2c(Nc3ccc(F)c(C)c3)ncnc2cc1O

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 10/20 0.73
RET P07949 8/20 0.73
EGFR P00533 8/20 0.73
KIF5B P33176 7/20 0.73
RIPK2 O43353 2/20 0.73
NOD1 Q9Y239 1/20 0.73
FBP1 P09467 2/20 0.64
AURKB Q96GD4 2/20 0.64
CLK1 P49759 2/20 0.64
AURKA O14965 1/20 0.64
ERBB2 P04626 1/20 0.64
INSR P06213 1/20 0.64
PDGFRB P09619 1/20 0.64
FLT4 P35916 1/20 0.64
EPHB4 P54760 1/20 0.64
TEK Q02763 1/20 0.64
JAK3 P52333 2/20 0.63
GAK O14976 1/20 0.63
STK10 O94804 1/20 0.63
FLT3 P36888 1/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15241078 0.88 EGFR (0.61) KDRRETEGFRKIF5BRIPK2
SCHEMBL3238800 0.88 EGFR (0.83) KDRRETEGFRKIF5BRIPK2
SCHEMBL9478 0.86 EGFR (0.77) KDRRETEGFRKIF5BRIPK2
SCHEMBL14159636 0.86 KDR (0.73) KDRRETEGFRKIF5BRIPK2
SCHEMBL17921478 0.84 EGFR (0.60) KDRRETEGFRKIF5BRIPK2
SCHEMBL20792806 0.84 EGFR (0.87) KDRRETEGFRKIF5BRIPK2
SCHEMBL12846249 0.84 EGFR (0.64) KDRRETEGFRKIF5BRIPK2
SCHEMBL24948889 0.84 EGFR (0.66) KDRRETEGFRKIF5BRIPK2
SCHEMBL6068633 0.83 KDR (0.82) KDRRETEGFRKIF5BRIPK2
SCHEMBL14964757 0.83 EGFR (0.81) KDRRETEGFRKIF5BRIPK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170226099-A1 QUINAZOLINE DERIVATIVE CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) 2017-08-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170226099-A1 QUINAZOLINE DERIVATIVE H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TOP2A, TOP1 KDR 3669/4885RET 4595/4885EGFR 3701/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.